---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-044349"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T16:53:39.561506+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q1 net revenue down 27.6% to $10.7M; cash $349.7M, runway to 2028

## Summary
- Net loss of $64.1M ($0.38 per share) vs. $64.8M ($0.49) in Q1 2024; R&D expenses doubled to $42.9M on wet AMD trials.
- DEXTENZA sales fell 27.7% to $10.6M due to pricing strategy, MIPS inclusion; quarterly sales expected to rise for rest of 2025.
- SOL-1 (Phase 3 wet AMD) topline data on track for 1Q 2026; FDA accepted SPA amendment allowing re-dosing at Weeks 52 and 76.
- SOL-R enrollment strong after target cut to ~555 subjects; remains 90% powered for non-inferiority; expedited NDA submission possible.
- Positive FDA feedback on potential AXPAXLI registrational trial in NPDR; company planning next steps in NPDR and DME.

## SEC filing metadata
- accession: 0001104659-25-044349
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/0001104659-25-044349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/tm2513949d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-044349
- JSON: https://secwatch.observer/filing/0001104659-25-044349.json
- Plain text: https://secwatch.observer/filing/0001104659-25-044349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.